

LAB #: F131206-0017-1
 PATIENT: Jonathan Barnett
 ID: P133400016
 SEX: Male
 DOB: 06/30/1956 AGE: 57

CLIENT#: 24510

Comprehensive Stool Analysis / Parasitology x2

BACTERIOLOGY CULTURE

Expected/Beneficial flora	Commensal (Imbalanced) flora	Dysbiotic flora
3+ Bacteroides fragilis group	2+ Alpha hemolytic strep	
4+ Bifidobacterium spp.	1+ Staphylococcus aureus	
1+ Escherichia coli		
2+ Lactobacillus spp.		
2+ Enterococcus spp.		
1+ Clostridium spp.		
NG = No Growth		

BACTERIA INFORMATION

Expected /Beneficial bacteria make up a significant portion of the total microflora in a healthy & balanced GI tract. These beneficial bacteria have many health-protecting effects in the GI tract including manufacturing vitamins, fermenting fibers, digesting proteins and carbohydrates, and propagating anti-tumor and anti-inflammatory factors.

Clostridia are prevalent flora in a healthy intestine. Clostridium spp. should be considered in the context of balance with other expected/beneficial flora. Absence of clostridia or over abundance relative to other expected/beneficial flora indicates bacterial imbalance. If *C. difficile* associated disease is suspected, a Comprehensive Clostridium culture or toxigenic *C. difficile* DNA test is recommended.

Commensal (Imbalanced) bacteria are usually neither pathogenic nor beneficial to the host GI tract. Imbalances can occur when there are insufficient levels of beneficial bacteria and increased levels of commensal bacteria. Certain commensal bacteria are reported as dysbiotic at higher levels.

Dysbiotic bacteria consist of known pathogenic bacteria and those that have the potential to cause disease in the GI tract. They can be present due to a number of factors including: consumption of contaminated water or food, exposure to chemicals that are toxic to beneficial bacteria; the use of antibiotics, oral contraceptives or other medications; poor fiber intake and high stress levels.

YEAST CULTURE

Normal flora

No yeast isolated

Dysbiotic flora

C# 018283

MICROSCOPIC YEAST

Result: Expected:
 Mod None - Rare

The microscopic finding of yeast in the stool is helpful in identifying whether there is proliferation of yeast. Rare yeast may be normal; however, yeast observed in higher amounts (few, moderate, or many) is abnormal.

YEAST INFORMATION

Yeast normally can be found in small quantities in the skin, mouth, intestine and mucocutaneous junctions. Overgrowth of yeast can infect virtually every organ system, leading to an extensive array of clinical manifestations. Fungal diarrhea is associated with broad-spectrum antibiotics or alterations of the patient's immune status. Symptoms may include abdominal pain, cramping and irritation. When investigating the presence of yeast, disparity may exist between culturing and microscopic examination. Yeast are not uniformly dispersed throughout the stool, this may lead to undetectable or low levels of yeast identified by microscopy, despite a cultured amount of yeast. Conversely, microscopic examination may reveal a significant amount of yeast present, but no yeast cultured. Yeast does not always survive transit through the intestines rendering it unviable.

Comments:

Date Collected: 12/05/2013
 Date Received: 12/06/2013
 Date Completed: 12/18/2013

* *Aeromonas, Campylobacter, Plesiomonas, Salmonella, Shigella, Vibrio, Yersinia, & Edwardsiella tarda* have been specifically tested for and found absent unless reported.





The Great Plains Laboratory, Inc.

LAB #: F131206-0017-1

PATIENT: Jonathan Barnett

ID: P133400016

SEX: Male

DOB: 06/30/1956

AGE: 57

CLIENT#: 24510

Comprehensive Stool Analysis / Parasitology x2

PARASITOLOGY/MICROSCOPY *

Sample 1

None Ova or Parasites

Sample 2

None Ova or Parasites

Rare RBC

Mod Yeast

*A trichrome stain and concentrated iodine wet mount slide is read for each sample submitted.

PARASITOLOGY INFORMATION

Intestinal parasites are abnormal inhabitants of the gastrointestinal tract that have the potential to cause damage to their host. The presence of any parasite within the intestine generally confirms that the patient has acquired the organism through fecal-oral contamination. Damage to the host includes parasitic burden, migration, blockage and pressure. Immunologic inflammation, hypersensitivity reactions and cytotoxicity also play a large role in the morbidity of these diseases. The infective dose often relates to severity of the disease and repeat encounters can be additive.

There are two main classes of intestinal parasites, they include protozoa and helminths. The protozoa typically have two stages; the trophozoite stage that is the metabolically active, invasive stage and the cyst stage, which is the vegetative inactive form resistant to unfavorable environmental conditions outside the human host. Helminths are large, multicellular organisms. Like protozoa, helminths can be either free-living or parasitic in nature. In their adult form, helminths cannot multiply in humans.

In general, acute manifestations of parasitic infection may involve diarrhea with or without mucus and or blood, fever, nausea, or abdominal pain. However these symptoms do not always occur. Consequently, parasitic infections may not be diagnosed or eradicated. If left untreated, chronic parasitic infections can cause damage to the intestinal lining and can be an unsuspected cause of illness and fatigue. Chronic parasitic infections can also be associated with increased intestinal permeability, irritable bowel syndrome, irregular bowel movements, malabsorption, gastritis or indigestion, skin disorders, joint pain, allergic reactions, and decreased immune function.

In some instances, parasites may enter the circulation and travel to various organs causing severe organ diseases such as liver abscesses and cysticercosis. In addition, some larval migration can cause pneumonia and in rare cases hyper infection syndrome with large numbers of larvae being produced and found in every tissue of the body.

One negative parasitology x1 specimen does not rule out the possibility of parasitic disease, parasitology x3 is recommended. This exam is not designed to detect *Cryptosporidium* spp, *Cyclospora cayetanensis* or *Microsporidia* spp.

GIARDIA/CRYPTOSPORIDIUM IMMUNOASSAY

	Within	Outside	Reference Range
Giardia intestinalis	Neg		Neg
Cryptosporidium	Neg		Neg

Giardia intestinalis (lamblia) is a protozoan that infects the small intestine and is passed in stool and spread by the fecal-oral route. Waterborne transmission is the major source of giardiasis.

Cryptosporidium is a coccidian protozoa that can be spread from direct person-to-person contact or waterborne transmission.

Comments:

Date Collected: 12/05/2013

Date Received: 12/06/2013

Date Completed: 12/18/2013

Analyzed by ©DOCTOR'S DATA, INC. • ADDRESS: 3755 Illinois Avenue, St. Charles, IL 60174-2420 • CLIA ID NO: 14D0646470 • MEDICARE PROVIDER NO: 148453

0001816

323609

Comprehensive Stool Analysis / Parasitology x2

DIGESTION / ABSORPTION

	Within	Outside	Reference Range
Elastase		188	> 200 µg/mL
Fat Stain	None		None - Mod
Muscle fibers	None		None - Rare
Vegetable fibers	None		None - Few
Carbohydrates	Neg		Neg

Elastase findings can be used for the diagnosis or the exclusion of exocrine pancreatic insufficiency. Correlations between low levels and chronic pancreatitis and cancer have been reported. **Fat Stain:** Microscopic determination of fecal fat using Sudan IV staining is a qualitative procedure utilized to assess fat absorption and to detect steatorrhea. **Muscle fibers** in the stool are an indicator of incomplete digestion. Bloating, flatulence, feelings of "fullness" may be associated with increase in muscle fibers. **Vegetable fibers** in the stool may be indicative of inadequate chewing, or eating "on the run". **Carbohydrates:** The presence of reducing substances in stool specimens can indicate carbohydrate malabsorption.

INFLAMMATION

	Within	Outside	Reference Range
Lysozyme*	183		<= 600 ng/mL
Lactoferrin		23.6	< 7.3 µg/mL
White Blood Cells	None		None - Rare
Mucus	Neg		Neg

Lysozyme* is an enzyme secreted at the site of inflammation in the GI tract and elevated levels have been identified in IBD patients. **Lactoferrin** is a quantitative GI specific marker of inflammation used to diagnose and differentiate IBD from IBS and to monitor patient inflammation levels during active and remission phases of IBD. **White Blood Cells (WBC):** in the stool are an indication of an inflammatory process resulting in the infiltration of leukocytes within the intestinal lumen. WBCs are often accompanied by mucus and blood in the stool. **Mucus** in the stool may result from prolonged mucosal irritation or in a response to parasympathetic excitability such as spastic constipation or mucous colitis.

IMMUNOLOGY

	Within	Outside	Reference Range
Secretory IgA*		14.8	51 - 204mg/dL

Secretory IgA* (sIgA) is secreted by mucosal tissue and represents the first line of defense of the GI mucosa and is central to the normal function of the GI tract as an immune barrier. Elevated levels of sIgA have been associated with an upregulated immune response.

Comments:

Date Collected: 12/05/2013
 Date Received: 12/06/2013
 Date Completed: 12/18/2013

*For Research Use Only. Not for use in diagnostic procedures.



The Great Plains Laboratory, Inc.

LAB #: F131206-0017-1

PATIENT: Jonathan Barnett

ID: P133400016

SEX: Male

DOB: 06/30/1956

AGE: 57

CLIENT#: 24510

Comprehensive Stool Analysis / Parasitology x2

SHORT CHAIN FATTY ACIDS

	Within	Outside	Reference Range
% Acetate	49		36 - 74 %
% Propionate	23		9 - 32 %
% Butyrate	24		9 - 39 %
% Valerate	4.2		1 - 8 %
Butyrate	1.2		0.8 - 3.8 mg/mL
Total SCFA's	4.8		4 - 14 mg/mL

Short chain fatty acids (SCFAs): SCFAs are the end product of the bacterial fermentation process of dietary fiber by beneficial flora in the gut and play an important role in the health of the GI as well as protecting against intestinal dysbiosis. Lactobacilli and bifidobacteria produce large amounts of short chain fatty acids, which decrease the pH of the intestines and therefore make the environment unsuitable for pathogens, including bacteria and yeast. Studies have shown that SCFAs have numerous implications in maintaining gut physiology. SCFAs decrease inflammation, stimulate healing, and contribute to normal cell metabolism and differentiation. Levels of **Butyrate** and **Total SCFA** in mg/mL are important for assessing overall SCFA production, and are reflective of beneficial flora levels and/or adequate fiber intake.

INTESTINAL HEALTH MARKERS

	Within	Outside	Reference Range
Red Blood Cells	Rare		None - Rare
pH	7.3		6 - 7.8
Occult Blood	Neg		Neg

Red Blood Cells (RBC) in the stool may be associated with a parasitic or bacterial infection, or an inflammatory bowel condition such as ulcerative colitis. Colorectal cancer, anal fistulas, and hemorrhoids should also be ruled out.

pH: Fecal pH is largely dependent on the fermentation of fiber by the beneficial flora of the gut.

Occult blood: A positive occult blood indicates the presence of free hemoglobin found in the stool, which is released when red blood cells are lysed.

MACROSCOPIC APPEARANCE

	Appearance	Expected
Color	Red/Orange	Brown
Consistency	Soft	Formed/Soft

Color: Stool is normally brown because of pigments formed by bacteria acting on bile introduced into the digestive system from the liver. While certain conditions can cause changes in stool color, many changes are harmless and are caused by pigments in foods or dietary supplements. **Consistency:** Stool normally contains about 75% water and ideally should be formed and soft. Stool consistency can vary based upon transit time and water absorption.

INTRODUCTION

This analysis of the stool specimen provides fundamental information about the overall gastrointestinal health of the patient. When abnormal microflora or significant aberrations in intestinal health markers are detected, specific interpretive paragraphs are presented. If no significant abnormalities are found, interpretive paragraphs are not presented.

Beneficial Flora

One or more of the expected (beneficial) bacteria are low in this specimen. Beneficial flora include lactobacilli, bifidobacteria, clostridia, *Bacteroides fragilis* group, enterococci, and some strains of *Escherichia coli*. The beneficial flora have many health-protecting effects in the gut, and as a consequence, are crucial to the health of the whole organism. Some of the roles of the beneficial flora include digestion of proteins and carbohydrates, manufacture of vitamins and essential fatty acids, increase in the number of immune system cells, break down of bacterial toxins and the conversion of flavinoids into anti-tumor and anti-inflammatory factors. Lactobacilli, bifidobacteria, clostridia, and enterococci secrete lactic acid as well as other acids including acetate, propionate, butyrate, and valerate. This secretion causes a subsequent decrease in intestinal pH, which is crucial in preventing an enteric proliferation of microbial pathogens, including bacteria and yeast. Many GI pathogens thrive in alkaline environments. Lactobacilli also secrete the antifungal and antimicrobial agents lactocidin, lactobacillin, acidolin, and hydrogen peroxide. The beneficial flora of the GI have thus been found useful in the inhibition of microbial pathogens, prevention and treatment of antibiotic associated diarrhea, prevention of traveler's diarrhea, enhancement of immune function, and inhibition of the proliferation of yeast.

In a healthy balanced state of intestinal flora, the beneficial flora make up a significant proportion of the total microflora. Healthy levels of each of the beneficial bacteria are indicated by either a 3+ or 4+ (0 to 4 scale). However, some individuals have low levels of beneficial bacteria and an overgrowth of nonbeneficial (imbalances) or even pathogenic microorganisms (dysbiosis). Often attributed to the use of antibiotics, individuals with low beneficial bacteria may present with chronic symptoms such as irregular transit time, irritable bowel syndrome, bloating, gas, chronic fatigue, headaches, autoimmune diseases (e.g., rheumatoid arthritis), and sensitivities to a variety of foods. Treatment may include the use of probiotic supplements containing various strains of lactobacilli, bifidobacteria and enterococci and consumption of cultured or fermented foods including yogurt, kefir, miso, tempeh and tamari sauce. Polyphenols in green and ginseng tea have been found to increase the numbers of beneficial bacteria. If dysbiosis is present, treatment may also include the removal of pathogenic bacteria, yeast, or parasites.

Percival M. Intestinal Health. Clin Nutr In. 1997;5(5):1-6.

Fuller R. Probiotics in Human Medicine. Gut. 1991;32: 439-442.

Siltonen S, Vapaatalo H, Salminen S, et al. Effect of Lactobacilli GG Yoghurt in Prevention of Antibiotic Associated Diarrhea. Ann Med. 1990; 22:57-59.

Oksanen P, Salminen S, Saxelin M, et al. Prevention of Travelers' Diarrhea by *Lactobacillus* GG. *Ann Med*. 1990; 22:53-56.

Perdigon G, Alvarez M, et al. The Oral Administration of Lactic Acid Bacteria Increases the Mucosal Intestinal Immunity in Response to Enteropathogens. *J Food Prot*. 1990;53:404-410.

Valeur N, et al. Colonization and Immunomodulation by *Lactobacillus reuteri* ATCC 55730 in the Human Gastrointestinal Tract. *Appl Environ. Microbiol*. 2004 Feb; 70(2):1176-81.

Elmer G, Surawicz C, and McFarland L. Biotherapeutic agents - a Neglected Modality for the Treatment and Prevention of Intestinal and Vaginal Infections. *JAMA*. 1996; 275(11):870-876.

Fitzsimmons N and Berry D. Inhibition of *Candida albicans* by *Lactobacillus acidophilus*: Evidence for Involvement of a Peroxidase System. *Microbio*. 1994; 80:125-133

Weisburger JH. *Proc Soc Exp Biol Med* 1999;220(4):271-5.

Imbalanced flora

Imbalanced flora are those bacteria that reside in the host gastrointestinal tract and neither injure nor benefit the host. Certain dysbiotic bacteria may appear under the imbalances category if found at low levels because they are not likely pathogenic at the levels detected. When imbalanced flora appear, it is not uncommon to find inadequate levels of one or more of the beneficial bacteria and/or a fecal pH which is more towards the alkaline end of the reference range (6.5 - 7.2). It is also not uncommon to find hemolytic or mucoid *E. coli* with a concomitant deficiency of beneficial *E. coli* and alkaline pH, secondary to a mutation of beneficial *E. coli* in alkaline conditions (DDI observations). Treatment with antimicrobial agents is unnecessary unless bacteria appear under the dysbiotic category.

Mackowiak PA. The normal microbial flora. *N Engl J Med*. 1982;307(2):83-93.

Microscopic yeast

Microscopic examination has revealed yeast in this stool sample. The microscopic finding of yeast in the stool is helpful in identifying whether the proliferation of fungi, such as *Candida albicans*, is present. Yeast is normally found in very small amounts in a healthy intestinal tract. While small quantities of yeast (reported as none or rare) may be normal, yeast observed in higher amounts (few, moderate to many) is considered abnormal.

An overgrowth of intestinal yeast is prohibited by beneficial flora, intestinal immune defense (secretory IgA), and intestinal pH. Beneficial bacteria, such as *Lactobacillus* colonize in the intestines and create an environment unsuitable for yeast by producing acids, such as lactic acid, which lowers intestinal pH. Also, *lactobacillus* is capable of releasing antagonistic substances such as hydrogen peroxide, lactocidin, lactobacillin, and acidolin.

Many factors can lead to an overgrowth of yeast including frequent use of antibiotics (leading to insufficient beneficial bacteria), synthetic corticosteroids, oral contraceptives, and diets high in sugar. Although there is a wide range of symptoms which can result from intestinal yeast overgrowth, some of the most common include brain fog, fatigue, recurring vaginal or bladder infections, sensitivity to smells (perfumes, chemicals, environment), mood swings/depression, sugar and carbohydrate cravings, gas/bloating, and constipation or loose stools.

A positive yeast culture (mycology) and sensitivity to prescriptive and natural agents is helpful in determining which anti-fungal agents to use as part of a therapeutic treatment plan for chronic colonic yeast. However, yeast are colonizers and do not appear to be dispersed uniformly throughout the stool. Yeast may therefore be observed microscopically, but not grow out on culture even when collected from the same bowel movement.

Elastase (low)

The level of Elastase is abnormally low in this specimen. Elastase is a pancreatic enzyme that digests and degrades a number of proteins. A finding of low elastase is an indicator of pancreatic exocrine insufficiency. Moderate pancreatic insufficiency is defined at 100-200 ug/g, and severe pancreatic insufficiency as <100 ug/g [1,2].

Fecal Elastase measured by a sensitive immunoassay is a specific marker for pancreatic function [1,3,4] and maintains a high diagnostic accuracy among patients with small intestinal diseases [5]. This Elastase marker allows for the diagnosis or exclusion of pancreatic exocrine insufficiency and degree of severity, which can be caused by chronic pancreatitis, cystic fibrosis, pancreatic tumor, cholelithiasis or diabetes mellitus [6,7,8]. This test does not differentiate between pancreatic insufficiency due to chronic pancreatitis and that due to pancreatic cancer [9]. Immunoreactive elastase concentrations are similar for children and adults [3].

In cases of severe exocrine pancreatic insufficiencies, triglycerides and/or steatocrit may also be elevated. Supplementation with pancreatic enzymes, minerals, and vitamins may be warranted.

1. Garcia-Bueno C, Rossi T, Lee K, Yuwono M, Robinson A, Tjota A. Quantification of fecal elastase-1 using either polyclonal or monoclonal antibodies. *AGA Abstracts, Gastroenterology* 2002;122(4):A-510.
2. Dominguez-Munoz J, Hieronymus C, Sauerbruch T, Malfertheiner P. Fecal Elastase: Evaluation of a new noninvasive pancreatic function test. *Am J Gastroenterol* 1995;90:1834-7.
3. Miendje Y, Maisin D, Sipewa MJ, Deprez P, Buts JP, De Nayer P, Philippe M. Polyclonal versus monoclonal ELISA for the determination of fecal elastase 1: diagnostic value in cystic fibrosis and chronic pancreatic insufficiency. *Clin Lab* 2004;50(7-8):419-424.
4. Gullo L, Ventrucci M, Tomassetti P, Migliori M, Pezzilli R. Fecal elastase1 determination in chronic pancreatitis. *Dig Dis Sci*. 2000;45(1):166-167.
5. Carroccio A, Verghi F, Santini B, Lucidi V, Iacono G, Cavataio F, Soresi M, Ansaldo N, Castro M, Montalto G. Diagnostic accuracy of fecal elastase 1 assay in patients with pancreatic maldigestion or intestinal malabsorption. *Digestive Diseases and Sciences* 2001; 46(6):1335-1342, 2001.
6. Glassbrenner B, Schon A, Klatt S, Beckh K, Adler G. Clinical evaluation of the faecal elastase test in the diagnosis and status of chronic pancreatitis. *Eur J Gastroenterol Hepatol*

1996;8(11):1117-20.

7. Deprez P, Del Natale M, Deji Y, Pauwels S, Philippe M. Comparative evaluation of C-mixed triglyceride breath test and faecal elastase1 tests I the assessment of exocrine pancreatic insufficiency. AGA Abstracts, Gastroenterology 2002;122(4):A-510.
8. Nunes AC, Pontes JM, Rosa A, Gomes L, Carnevalheiro M, Freitas D. Screening for pancreatic exocrine insufficiency in patients with diabetes mellitus. Am J Gastroenterol 2003;98(12):2672-2675.
9. Stein J, Jung M, Sziegoleit A, Zeuzem S, Capary W, Lembcke B. Immunoreactive elastase I: clinical evaluation of a new noninvasive test of pancreatic function. Clinical Chemistry 1996;42(2):222-226.

Fecal Lactoferrin

The level of fecal lactoferrin, a biomarker of serious gastrointestinal inflammation, is abnormally high in this fecal sample. Fecal lactoferrin is elevated in association with Inflammatory Bowel Disease (IBD) such as Ulcerative Colitis (UC) or Crohn's Disease (CD)[1,2], but NOT Irritable Bowel Syndrome (IBS)[1,3]. Therefore, assessment of fecal lactoferrin levels enables distinction between IBD and non-inflammatory IBS. Such distinction is critical because, although both IBD and IBS may share some common symptoms such as diarrhea, abdominal cramping and weight loss, the diseases are treated quite differently. IBD may become life threatening, requires life long treatment and possibly surgery. In contrast, IBS is often effectively treated with dietary restrictions, stress reduction and medication.

Gastrointestinal inflammation associated with IBD is associated with increased infiltration of activated neutrophils into the mucosa and increased release of lactoferrin into the gut[1,4,5]. Patients with inflammation of the GI tract, such as IBD (but not IBS), exhibit elevated lactoferrin concentrations in the feces[1].

Clinical studies have shown that fecal lactoferrin levels of healthy persons are similar to IBS patients, but markedly increased in patients with active IBD[1,3]. Patients with IBD oscillate between active and inactive disease states, and fecal lactoferrin levels increase 2-3 weeks prior to onset of clinical symptoms[6]. During remission and effective treatment, fecal lactoferrin decreases significantly. Therefore disease activity, and efficacy of treatment can be monitored by following fecal lactoferrin levels. The test can be ordered separately to track disease activity in patients with IBD.

Moderately elevated levels of fecal lactoferrin can occur, with fecal red blood cells and leukocytes, in association with invasive enteropathogens [7,8]. Such levels would be expected to be much lower than those associated with the active phase of IBD. Therefore, with moderately elevated levels of fecal lactoferrin, one should check for the presence of enteropathogens (eg. Shigella, Campylobacter, Clostridium difficile).

Guidelines for interpreting the results of this test are provided by the results of a large multi-center clinical study which evaluated fecal lactoferrin levels in 180 patients suffering with IBS and IBD (UC and CD) compared to 56 healthy controls.

GROUP	# of SPECIMENS	FECAL LACTOFERRIN
		mean mcg/ml +/- SE
Inactive UC	41	67 +/- 24
Active UC	31	815 +/- 789
Inactive CD	26	239 +/- 83
Active CD	51	672 +/- 242
IBS	31	1.3 +/- 0.3
Healthy Controls	55	1.6 +/- 0.4

1. Kane, S.V., Sandborn, W.J., Rufo, P.A., et al. Am. J. Gastroenterol. (2003)98(6):1309-14.
2. Sugi, K., Saitoh, O., Hirata, I., et al. Am. J. Gastroenterol. (1996)91(5):927-33.
3. Buderus, S., Lohmann, N., Boone, J. et al. Suppl. Gastroenterol. (2002)122:A-219:St392.
4. Baveye, S., Ellass, e., Mamurer, J. et al. Clin. Lab. Med. (1999) 37:281-6.
5. Fine, K.D., Ogunji, G., Niehaus, M. et al. Am J. Gastroenterol. (1993):1300-05.
6. Walker, T., Sandborn, W., Boone, J., et al. Am J. Gastroenterol. (2003)98:S246:742
7. Huicho, L., Garaycochea, V., Uchima, N. et al. Ped. Infect. Dis. J. (1997)16(7):644-7.
8. Guerrant, R.L., Araujo, V., Soares, E. et al. J. Clin. Microbiol. (1992)30(5):1238-42.

Secretory IgA (sIgA)

The concentration of sIgA is abnormally low in this specimen. Immunological activity in the gastrointestinal tract can be assessed using secretory immunoglobulin A (sIgA). Secretory IgA is the predominant antibody, or immune protein the body manufactures and releases in external secretions such as saliva, tears, and milk [1]. It is also transported through the epithelial cells that line the intestines out into the lumen. Secretory IgA represents the first line of defense of the GI mucosa and is central to the normal function of the GI tract as an immune barrier [1]. As the principal immunoglobulin isotype present in mucosal secretions, sIgA plays an important role in controlling intestinal milieu which is constantly presented with potentially harmful antigens such as pathogenic bacteria, parasites, yeast, viruses, abnormal cell antigens.

and allergenic proteins [1]. Secretory IgA antibodies exert their function by binding to antigenic epitopes on the invading microorganism, limiting their mobility and adhesion to the epithelium of the mucus membrane [2]. This prevents the antigens from reaching systemic circulation and allowing them to be excreted directly in the feces.

Mental and physical stress as well as inadequate nutrition have been associated with low fecal sIgA concentrations. This includes dietary restrictions, excessive alcohol intake, body mass loss, negative moods, and anxiety [3]. One study found depressed levels of sIgA in malnourished children, particularly protein malnourishment, that responded well to nutritional rehabilitation with a significant increase in sIgA [4]. This may be because the synthesis and expression of sIgA requires adequate intake of the amino acid L-glutamine [3]. Animal studies have demonstrated that a glutamine-restricted diet can result in a 50% decrease in sIgA levels [5]. An increase of dietary L-glutamine can restore GI immune function by protection of cells that synthesize sIgA [6]. *Saccharomyces boulardii* is a nonpathogenic yeast that has been used for the treatment of acute infectious enteritis and antibiotic-associated diarrhea [7]. Significantly elevated levels of sIgA and subsequent enhanced host immune response have been found following *S. boulardii* administration in mice and rats [8,9].

References:

1. Crago SS, Tomasi TB. Mucosal Antibodies, Food Allergy and Intolerance. Bailliere Tindall/W.B. Saunders 1987;167-89.
2. Roberts JA. Factors predisposing to urinary tract infections in children. *Ped Neph* 1996;10:517-522.
3. Carins J, Booth C. Salivary immunoglobulin-A as a marker of stress during strenuous physical training. *Aviat Space Environ Med* 2002;73(12)1203-7.
4. Teodosio MR, Oliveira ECM. Urinary secretory IgA after nutritional rehabilitation. *Braz J Med Biolog Res* 1999;32:421-426
5. Alverdy J. Effects of glutamine-supplemented diets on immunology of the gut. *J Parent Enteral Nutr* 1990;14(4):1095-1135.
6. Burke DJ, et al. Glutamine-supplemented total parenteral nutrition improves gut function. *Arch Surg* 1989;24:2396-2399.
7. Alverdy JA. The effect of total parenteral nutrition on gut lamina propria cells. *J Parent. Enteral Nutr* 1990;14(suppl).
8. Qamar A, Aboudola S, Wamy M, et al. *Saccharomyces boulardii* stimulates intestinal immunoglobulin A immune response to clostridium difficile toxin A in mice. *Infect Immun* 2001;69(4):2762-5.
9. Buts JP, Bernasconi P, Vaerman JP, et al. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with *Saccharomyces boulardii*. *Dig Dis Sci* 1990;35(2):251-6.

pH high

The pH of this stool sample was found to be too alkaline (>7.2). Ideally, the pH of the stool is slightly acidic. This represents colonic pH, which is largely reflective of bacterial fermentation and putrefaction of intestinal contents. Healthy microflora such as *Lactobacillus* and *Bifidus* generate large amounts of short chain fatty acids (acetic, propionic, butyric, and valeric), which

lower or acidify colonic pH. The short chain fatty acids are byproducts of the bacterial fermentation process of dietary fiber by beneficial flora in the gut. The major factors that can contribute to an alkaline pH include decreased levels of beneficial flora and inadequate dietary fiber intake. Changes in fat and protein intake do not appear to directly alter fecal pH [1,2].

Many G.I. pathogens, including bacteria and yeast, thrive in an alkaline pH. When fecal pH is more towards the alkaline end of the reference range, it is not uncommon to find inadequate levels of one or more of the beneficial bacteria (0 to 2+) and possibly imbalanced flora, dysbiotic bacteria and/or yeast present.

Numerous studies have indicated that increased colonic pH may be a risk factor for colorectal cancer [2-5]. Certain colonic bacteria are able to degrade bile acids, and possibly cholesterol metabolites, into carcinogens [6]. The conversion of bile acids into secondary carcinogenic metabolites occurs by 7-dehydroxylation [3]. This process has been demonstrated to be inhibited in vitro [7,8] below pH 6.5 and possibly in vivo [9]. Dietary fiber protects against colorectal cancer by reducing colonic pH via bacterial fermentation and subsequent short fatty acid production. Production of the short chain fatty acid butyrate is also important for proper differentiation of colonocytes [10]. Fiber also aids in decreasing colonic transit time (reducing absorption of carcinogens) and increasing stool weight (decreasing carcinogen concentration) [11].

Studies indicate that the type of fiber (e.g. wheat bran, oat bran, high-amylose starch, or indigestible oligosaccharides) is important in determining the pH and short chain fatty acid content of the stool [12,13]. Additionally, a study of elderly patients demonstrated that administration of tea catechins, given as a dietary supplement, significantly lowered fecal pH [14].

1. Walker AR, Walker BF, Segal I. Faecal pH value and its modification by dietary means in South African black and white schoolchildren. *S Afr Med J* 1979;55(13):495-8.
2. Malholtra SL. Faecal urobilinogen levels and pH of stools in population groups with different incidence of cancer of the colon, and their possible role in its aetiology. *J R Soc Med* 1982;75(9):709-14.
3. Thornton JR. High colonic pH promotes colorectal cancer. *Lancet* 1981;1(8229):1081-3.
4. Walker ARP, Walker BF, Walker AJ. Faecal pH, dietary fibre intake, and proneness to colon cancer in four South African populations. *Br J Cancer* 1986;53:489-495.
5. Kashtan H, Stern HS, Jenkins JA, et al. Manipulation of fecal pH by dietary means. *Preventive Medicine* 1990;19:607-613.
6. Hill MJ. Bacteria and the etiology of colon cancer. *Cancer* 1974;34:815-8.
7. Midvedt T, Norman A. Parameters in 7 α -dehydroxylation of bile acids by anaerobic lactobacilli. *Acta path Microbiol Scand* 1968;72:313-29.
8. Aries V, Hill MJ. Degradation of steroids by intestinal bacteria II. *Biochim Biophys Acta* 1970;202:535-43.
9. Thornton JR, Heaton KW. Do colonic bacteria contribute to cholesterol gallstone formation Effects of lactulose on bile. *Br Med J* 1981;i:1018-20.
10. Basson MD, Sgambati SA. Effects of short-chain fatty acids on human rectosigmoid

-
- mucosal colonocyte brush-border enzymes. *Metabolism* 1998;47(2):133-4.
11. Burkitt DP. Epidemiology of cancer of the colon and rectum. *Cancer* 1971;28:3-13.
 12. Campbell JM, Fahey GC, Wolf BW. Selected indigestible oligosaccharides affect large bowel mass, cecal and fecal short-chain fatty acids, pH and microflora in rats. *J Nutr* 1997;127(1):130-6.
 13. Noakes M, Clifton PM, Nestel PJ, et al. Effect of high-amylose starch and oat bran on metabolic variables and bowel function in subjects with hypertriglyceridemia. *Am J Clin Nutr* 1996;64(6):944-51.
 14. Goto K, Kanaya S, Ishigami T, et al. The effects of tea catechins on fecal conditions of elderly residents in a long-term care facility. *J Nutr Sci Vitaminol* 1999;45(1):135-41.